tiprankstipranks
I-MAB Engages Interim CEO in Strategic Agreement
Company Announcements

I-MAB Engages Interim CEO in Strategic Agreement

I-MAB (IMAB) has released an update.

Don't Miss our Black Friday Offers:

I-MAB Biopharma US Limited has entered into a six-month secondment agreement with ABio-X Holdings, Inc., effective July 15, 2024, where Sean Xi-Yong Fu will serve as interim CEO for I-MAB. The agreement outlines that Fu remains an employee of ABio-X with his salary and benefits paid by them, while I-MAB will compensate ABio-X for his services. The agreement may be renewed monthly and includes provisions for automatic termination, responsibilities, and confidentiality.

For further insights into IMAB stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskI-Mab’s Third Quarter Results: Progress in Cancer Immunotherapies
TipRanks Auto-Generated NewsdeskI-Mab’s Promising Q3 Results and Strategic Moves
TheFlyI-Mab reports Q3 EPS (25c) vs. (39c) last year
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App